Identification of Gene Signature in Peripheral Blood of Breast Cancer

YE Yun; ZHONG Yingying; SUN Yufei; ZHANG Qian

doi:10.3971/j.issn.1000-8578.2015.07.004

Cancer Research on Prevention and Treatment > 2015 > 42(07): 656-661. > DOI: 10.3971/j.issn.1000-8578.2015.07.004

YE Yun, ZHONG Yingying, SUN Yufei, ZHANG Qian. Identification of Gene Signature in Peripheral Blood of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(07): 656-661. DOI: 10.3971/j.issn.1000-8578.2015.07.004

Citation:

PDF (1529 KB)

Identification of Gene Signature in Peripheral Blood of Breast Cancer

College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou 545006, China

More Information

Received Date: October 19, 2014
Revised Date: January 26, 2015

Graphical Abstract

Abstract

Abstract

Objective To find out molecular signature in breast cancer(BC) for early detection by analyzing the gene expression profile in the peripheral blood of BC and healthy samples. Methods GSE11545 from GEO database was taken as training cohort in this paper. Differentially expressed genes between BC and healthy samples were obtained by BRB-ArrayTools software. And these genes were used as candidate genes to predict classification in validation cohort GSE27562 by four methods including compound covariate predictor, diagonal linear discriminant analysis, 3-nearest neighbors and support vector machine. Only genes significantly differed between the classes at 0.001 significance level were used for class prediction. Leave-oneout cross-validation method was used to compute mis-classification rate. Result of prediction was assessed with receiver operating characteristic(ROC) curve. Results Sixty-one differential genes were obtained from the training cohort. 39-gene classifier was used to predict validation cohort. The accuracy rate of classification reached or exceeded 80% with four methods. Areas under ROC curve were 0.925. The methods showed satisfactory classification result. Conclusion Microarray analysis is an effective method in screening gene signature in the peripheral blood of BC. It may provide a new method for diagnosing breast cancer in early stage.
- Breast cancer,
- Peripheral blood,
- Gene expression profile

FullText(HTML)

References (17)

References

[1]	Mo M, Liu GY, Lv LL, et al. Advances in breast cancer screening program[J]. Zhong Liu, 2012, 32(9): 748-54. [莫淼, 柳光宇, 吕力琅, 等. 乳腺癌筛查研究进展[J]. 肿瘤, 2012, 32(9): 748-54.]
[2]	Bundred NJ. Prognostic and predictive factors in breast cancer[J]. Cancer Treat Rev, 2001, 27(3): 137-42.
[3]	Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century[J]. Eur J Cancer, 1999, 35(14): 1963-73.
[4]	Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J]. Int J Cancer, 2010, 12 7(12): 2893-917.
[5]	Smetherman DH. Screening, imaging, and image-guided biopsy techniques for breast cancer[J]. Surg Clin North Am, 2013, 93(2): 30 9-27.
[6]	Huang XQ, Zeng H. Correlation between gene expression profiles of adenocarcinoma of esophagus and Barrett's esophagus[J]. Zhong Liu Fang Zhi Yan Jiu, 2009, 36(8): 639-42. [黄绪群, 曾辉. 食管腺癌与Barrett’s食管基因表达谱的研究[J]. 肿瘤防治研究, 20 09, 36(8): 639-42.]
[7]	Kuasela P, Haglund C, Ruberts PJ. Comparison of a new tumour marker CA242 with CA19-9, CA50 and carcinoembryonic antigen (CEA) in digestive tract disease[J]. Br J Cancer, 1991, 63 (4) : 636-40.
[8]	Chinese Society of Laboratory Medicine, National Center for Clinical Laboratories, Editorial Committee of Chinese Journal of Laboratory Medicine. Advice of tumor markers in clinical application[J]. Zhonghua Jian Yan Yi Xue Za Zhi, 2012, 35(2): 10 3-16. [中华医学会检验分会, 卫生部临床检验中心, 中华检验医学杂志编辑委员会.肿瘤标志物的临床应用建议[J]. 中华检验医学杂志, 2012, 35(2): 103-16.]
[9]	Sha L, Cao Y, Shi L. Usefulness of tumor markers CA153, CA125, CEA and AFP in early diagnosis of breast tumor by ROC curve[J]. Guo Ji Jian Yan Yi Xue Za Zhi, 2007, 28(11): 1039-40. [沙玲, 曹研, 施莉. 应用ROC曲线对肿瘤标志物CA153、CA125、CEA 和AFP在乳腺肿瘤早期诊断中的应用价值评价[J]. 国际检验医学杂志, 2007, 28(11): 1039-40.]
[10]	Zhang H, Xiang MJ, Mao SL, et al. The clinical value of the combined measurement of three serum tumor markers in breast cancer[J]. Zhongguo Shi Yan Zhen Duan Xue, 2011, 15(1): 96-8. [张华, 项明洁, 毛顺露, 等. 三项肿瘤标志物联合检测在乳腺癌诊断中的价值[J]. 中国实验诊断学, 2011, 15(1): 96-8.]
[11]	Shen Q, Song GH, Zhang JX, et al. Comprehensive evaluation of the diagnostic value of contrast-enhanced sonography for breast cancer by ROC curve and logistic regression[J]. Shi Yong Yi Xue Za Zhi, 2009, 25(7): 1058-60. [沈嫱, 宋光辉, 张建兴, 等. Logistic回归及ROC曲线综合评价超声造影对乳腺癌的诊断 [J] 实用医学杂志, 2009, 25(7): 1058-60.]
[12]	Karn T, Metzler D, Ruckhäberle E, et al. Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer[J]. Breast Cancer Res Treat, 2010, 12 0(3): 567-79.
[13]	Rody A, Karn T, Ruckhäberle E, et al. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer[J]. Breast Cancer Res Treat, 2009, 113(3): 457-66.
[14]	Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography[J]. Int J Cancer, 2002, 102(1): 91-5.
[15]	Hong X, Zhang YQ. Progress on JAK-STAT signaling pathway in cancer research[J]. Ji Chu Yi Xue Yu Lin Chuang, 2011, 31(4): 46 3-6. [洪璇, 张艳桥. JAK-STAT信号传导通路在肿瘤中的进展[J] 基础医学与临床, 2011, 31(4): 463-6.]
[16]	Zeng L. Progress on MARK signaling pathway in invasion and metastasis of tumor[J]. Zhong Liu Fang Zhi Yan Jiu, 2002, 29(5): 91 4-6. [曾亮. MAPK信号通路与肿瘤侵袭和转移研究进展[J]. 肿瘤防治研究, 2002, 29(5): 914-6.]
[17]	Xie BC, Li GL. Wnt gene/Wnt signaling pathway in breast cancer[J]. Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao, 2011, 27(2): 125-9. [谢碧琛, 李国利. Wnt基因/Wnt 通路与乳腺癌[J]. 中国生物化学与分子生物学报, 2011, 27(2): 12 5-9.]

[1]	LIN Jinlan, GUO Tianxing, PAN Xiaojie, XU Zhenwu. Clinical Observation of Metronomic Oral Vinorelbine Monotherapy as First-line Treatment on Elderly Patients with Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 909-912. DOI: 10.3971/j.issn.1000-8578.2018.18.0841
[2]	CHEN Pengcheng, MAO Weimin. Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(7): 609-615. DOI: 10.3971/j.issn.1000-8578.2016.07.014
[3]	Liu Mingyue, Hou Guiqin, Gao Tianhui, Cui Yao, Li Xiaoyan, Zhou Yun. Efficacy of Pemetrexed Chemotherapy in Advanced Non-small Cell Lung Cancer with EGFR-TKI Resistence[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 713-715. DOI: 10.3971/j.issn.1000-8578.2012.06.025
[4]	Tong Wanning, Zhang Jun, Zhuo Anshan, Cao Yushu. Clinical Effects of Whole Body Gamma Knife Combined with Pemetrexed Plus Carboplatin on Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(01): 81-84. DOI: 10.3971/j.issn.1000-8578.2012.01.021
[5]	WANG Ya-di, HA Min-wen, AN Yu-zhi, WANG Yue, CHENG Jian, LIU Wei. Clinical Observation of Gemcitabine Monotherapy in Treatment of Elder Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(06): 698-700. DOI: 10.3971/j.issn.1000-8578.2011.06.025
[6]	TAO Dan, LONG Zhi-xiong, WANG Bin, LIU Yan-ping, GAO Xia, HUANG Ya-li, WU Jing, HUANG Hui, WAN Huan. Clinical Effects of Accelerator Linear Plus Gamma Knife Radiotherapy Combined with Concurrent DP Regimen Chemotherapy for Locally Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 575-578. DOI: 10.3971/j.issn.1000-8578.2011.05.026
[7]	ZHAN Yong-zi, HUANG Chang-jie, HUANG Jian-feng. Clinical Observation of Erlotinib in Treatment of Patients with Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(04): 461-462. DOI: 10.3971/j.issn.1000-8578.2010.04.025
[8]	FU Xiao-min, WANG Jing, ZHANG Hui, BAO Ai-hua. Clinical Research for Docetaxel Plus Cisplatin in Untreated Adwanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 205-208. DOI: 10.3971/j.issn.1000-8578.2010.02.022
[9]	LI Hong-mei, GAO Ya-ling. Clinical Comparison of Three Different Chemotherapy Regimens Including Cisplain for Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2006, 33(09): 670-672. DOI: 10.3971/j.issn.1000-8578.1314
[10]	PAN Da-chao, XIE ZHong. The clinical study of combination chemotherapy with navelbine and ifosfamide in treating of advanced Non-small cell lung cancer[J]. Cancer Research on Prevention and Treatment, 2002, 29(03): 241-242. DOI: 10.3971/j.issn.1000-8578.3085

Cited By

Get Citation

PDF

XML

Article views (1304) PDF downloads (564)

Turn off MathJax

Article Contents

Abstract

References

Identification of Gene Signature in Peripheral Blood of Breast Cancer

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Identification of Gene Signature in Peripheral Blood of Breast Cancer

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content